Contact
Please use this form to send email to PR contact of this press release:
Opiant Pharmaceuticals Announces Top-line Results from Phase 2 Clinical Trial of OPNT001 for Treatment of Bulimia Nervosa
TO:
Please use this form to send email to PR contact of this press release:
Opiant Pharmaceuticals Announces Top-line Results from Phase 2 Clinical Trial of OPNT001 for Treatment of Bulimia Nervosa
TO: